YOKOGAMI Kiyotaka

写真a

Affiliation

Faculty of Medicine School of Medicine Department of Clinical Neuroscience, Neurosurgery

Title

Associate Professor

External Link

Degree 【 display / non-display

  • 博士(医学) ( 1997.11   宮崎医科大学 )

  • 医学士 ( 1989.3   宮崎医科大学 )

 

Papers 【 display / non-display

  • Importance of Age and Noncontrast-Enhancing Tumor as Biomarkers for Isocitrate Dehydrogenase-Mutant Glioblastoma: A Multicenter Study.

    Uetani H, Azuma M, Khant ZA, Watanabe Y, Kudo K, Kadota Y, Yokogami K, Takeshima H, Kuroda JI, Shinojima N, Hamasaki T, Mukasa A, Hirai T

    Journal of computer assisted tomography   2023.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/RCT.0000000000001456

    PubMed

  • Proposed System for Selection of Surgical Approaches for Craniopharyngiomas Based on the Optic Recess Displacement Pattern

    Watanabe T., Uehara H., Takeishi G., Chuman H., Azuma M., Yokogami K., Takeshima H.

    World Neurosurgery   170   e817 - e826   2023.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:World Neurosurgery  

    Objective: Craniopharyngiomas remain surgically challenging because of the strong adhesion to vital neurovascular structures. We propose a system for the selection of surgical approaches based on the optic recess (OR) displacement pattern to facilitate surgical planning and obtain optimum visual and endocrinologic outcomes. Methods: Craniopharyngiomas were divided into 3 types based on the OR displacement pattern: superior, anterior, and involvement types. Selected surgical approaches and patient outcome were retrospectively reviewed according to these classifications. Visual and endocrinologic outcomes were compared among the groups. Results: This study included 26 patients with primary craniopharyngiomas who underwent surgery at our institution, classified into 11 anterior, 11 superior, and 4 involvement types. The extended endoscopic endonasal approach provided excellent exposure inferodorsal aspect of the chiasm for manipulation of the dissection plane in the anterior and superior types with midline location. A unilateral subfrontal approach was required for tumor of the superior type with lateral extension. An interhemispheric translamina terminalis approach could provide safe dissection under direct vision of strong adhesion at the superior aspect of the chiasm in the involvement type. Visual and endocrinologic outcomes were better in the involvement type compared with the superior and anterior types. Visual outcome was significantly correlated with preoperative visual function. Conclusions: Craniopharyngiomas with the involvement type are indicated for the translamina terminalis approach to achieve the best visual and endocrinologic outcome. Our classification of the OR displacement pattern is useful to select the optimal surgical approach for craniopharyngiomas more accurately and concisely, especially in cases with third ventricular extension.

    DOI: 10.1016/j.wneu.2022.11.138

    Scopus

    PubMed

  • PBRM1 and BAP1: novel genetic mutations in malignant transformation of craniopharyngioma—a case report

    Tamura M., Yokogami K., Watanabe T., Kawano T., Muta J., Yamashita S., Oguri N., Sato Y., Takeshima H.

    Brain Tumor Pathology   40 ( 1 )   40 - 44   2023.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Brain Tumor Pathology  

    Malignant craniopharyngioma is especially rare, so the causes and genetic mutations associated with the malignant transformation have not been explained in detail. We investigated the molecular genetic characteristics of malignant transformation in craniopharyngioma. A 53-year-old man with a history of adamantinomatous craniopharyngioma presented with complaints of subcutaneous swelling. Magnetic resonance imaging showed a less enhanced intradural supra-sellar lesion and a heterogeneously well-enhanced extradural invasive lesion infiltrating the dura mater, brain, frontal bone, and subcutaneous tissue. Histopathological examination of the recurrent tumor revealed typical findings of both craniopharyngioma (intradural supra-sellar lesion) and malignant transformation, such as marked nuclear atypia with mitosis (invasive extradural lesion), which were not present in the primary tumor. A genetic panel test with the Oncopanel system was performed to investigate the genetic mutations responsible for the malignant transformation. Four genetic mutations were identified: CTNNB1 c.C98T, TP53 p.C135fs*35(PLS = 3 UPD/LOH), PBRM1 p.R1000*(PLS = 3 UPD/LOH), and BAP1 p.L650fs*5(PLS = 3 UPD/LOH). Sanger sequencing showed CTNNB1 in both the intradural supra-sellar and extradural invasive lesions, but TP53, PBRM1, and BAP1 only in the extradural invasive lesion. The genetic mutations of PBRM1 and BAP1 may be genetic factors in the malignant transformation of adamantinomatous craniopharyngioma.

    DOI: 10.1007/s10014-022-00444-3

    Scopus

    PubMed

  • Clinicopathologic analysis of pineal parenchymal tumors of intermediate differentiation: a multi-institutional cohort study by the Kyushu Neuro-Oncology Study Group

    Yamashita S., Takeshima H., Hata N., Uchida H., Shinojima N., Yokogami K., Nakano Y., Sakata K., Fudaba H., Enomoto T., Nakahara Y., Ujifuku K., Sugawara K., Iwaki T., Sangatsuda Y., Yoshimoto K., Hanaya R., Mukasa A., Suzuki K., Yamamoto J., Negoto T., Nakamura H., Momii Y., Fujiki M., Abe H., Masuoka J., Abe T., Matsuo T., Ishiuchi S.

    Journal of Neuro-Oncology   162 ( 2 )   425 - 433   2023

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Journal of Neuro-Oncology  

    Purpose: Pineal parenchymal tumors of intermediate differentiation (PPTIDs), which were recognized in the 2007 World Health Organization (WHO) classification, are rare, accounting for less than 1% of all central nervous system tumors. This rarity and novelty complicate the diagnosis and treatments of PPTID. We therefore aimed to evaluate the clinicopathological significance of this tumor. Methods: At 11 institutions participating in the Kyushu Neuro-Oncology Study Group, data for patients diagnosed with PPTID were collected. Central pathology review and KBTBD4 mutation analysis were applied to attain the diagnostically accurate cohort. Results: PPTID was officially diagnosed in 28 patients: 11 (39%) with WHO grade 2 and 17 (61%) with WHO grade 3 tumors. Median age was 49 years, and the male:female ratio was 1:2.1. Surgery was attempted in all 28 patients, and gross total resection (GTR) was achieved in 46% (13/28). Adjuvant radiotherapy and chemotherapy were administered to, respectively, 82% (23/28) and 46% (13/28). The 5-year progression-free survival (PFS) and overall survival rates were 64.9% and 70.4% respectively. Female sex (p = 0.018) and GTR (p < 0.01) were found to be independent prognostic factors for PFS and female sex (p = 0.019) was that for OS. Initial and second recurrences were most often leptomeningeal (67% and 100% respectively). 80% (20/25) of patients harbored a KBTBD4 mutation. Conclusions: Female sex and GTR were independent prognostic factors in our patients with PPTID. Leptomeningeal recurrence was observed to be particularly characteristic of this tumor. The rate of KBTBD4 mutation observed in our cohort was acceptable and this could prove the accuracy of our PPTID cohort.

    DOI: 10.1007/s11060-023-04310-w

    Scopus

    PubMed

  • Methionine regulates self-renewal, pluripotency, and cell death of GIC through cholesterol—rRNA axis

    Yokogami K., Kikuchi T., Watanabe T., Nakatake Y., Yamashita S., Mizuguchi A., Takeshima H.

    BMC Cancer   22 ( 1 )   1351   2022.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:BMC Cancer  

    Background: Glioma-initiating cells (GICs) are the source of glioma cells that can self-renew, have pluripotency, and are treatment-resistant, so are the starting point for relapse and eventual death despite multimodality therapy. L-[methyl-11C] methionine PET has observed high accumulation at the time of recurrence, it is important to understand the mechanism of tumor cell activation caused by the reorganization of methionine metabolism. Methods: We cultured cells in methionine-deprived culture medium for comprehensive analysis. Based on the obtained results, the possible target molecules were chemically inhibited and the respective markers were analyzed. Results: Methionine depletion markedly decreased proliferation and increased cell death of GICs. Decreased S-adenosyl-methionine, which is synthesized intracellularly by catalyzed by methionine adenosyltransferase using methionine, triggered the following: (i) global DNA demethylation, (ii) hyper-methylation of signaling pathways regulating pluripotency of stem cells, (iii) decreased expression of the core-genes and pluripotent markers of stem cells including FOXM1, SOX2, SOX4, PROM1, and OLIG2, (iv) decreased cholesterol synthesis and increased excretion mainly through decreased SREBF2, and (v) down-regulation of the large subunit of ribosomal protein configured 28S and ACA43, small nucleolar RNA guiding the pseudouridylation of 28S rRNA, which is essential for translation. In addition, inhibition of cholesterol synthesis with statin resulted in a phenotype similar to that of methionine depletion and decreases in stem cell markers and small nucleolar RNA ACA43. Moreover, suppression of FOXM1 decreased stem cell markers such as SOX4 and PROM1. The gene expression profile for cholesterol production was obtained from the Ivy Glioblastoma Atlas Project database and compared between tumor cells with relatively low methionine levels in areas of pseudopalisading arrangement around necrosis and tumor cells in the infiltrating region, showing that cells in the infiltrating region have higher capacity to produce cholesterol. Conclusions: Methionine metabolism is closely related with self-renewal, pluripotency, and cell death in GICs through modification of cholesterol biosynthesis, especially in the SREBF2-FOXM1 and ACA43 axis with modification of rRNA.

    DOI: 10.1186/s12885-022-10280-5

    Scopus

    PubMed

display all >>

Books 【 display / non-display

  • プライム脳神経外科Ⅰ 脳動脈瘤

    横上聖貴、竹島秀雄、外( Role: Joint author)

    三輪書店  2017 

     More details

    Language:Japanese Book type:Textbook, survey, introduction

  • プライム脳神経外科Ⅰ 脳動脈瘤

    横上聖貴、竹島秀雄、外( Role: Joint author)

    三輪書店  2017 

     More details

    Language:Japanese Book type:Textbook, survey, introduction

  • 別冊 日本臨床、新領域別症候群シリーズ No.28 神経症候群(第2版)(Ⅲ)-その他の神経疾患を含めて-.

    横上聖貴、竹島秀雄( Role: Joint author)

    日本臨牀社<大阪市>  2014.6 

     More details

    Language:Japanese

  • ブレインナーシング,夏季増刊号(共著)

    横上聖貴、竹島秀雄( Role: Joint author)

    メディカ出版  2010.8 

     More details

    Language:Japanese

MISC 【 display / non-display

  • Ⅵ.腫瘍性疾患 2.神経上皮性腫瘍        1)星細胞系腫瘍        2)毛様細胞性星細胞腫 【N399】

    横上聖貴、竹島秀雄

    日本臨牀 別冊 神経症候群(第2版)Ⅲ-その他の神経疾患を含めて-   2014.6

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   Publisher:日本臨牀社  

  • ポイントが簡単&早わかり!脳神経疾患のおくすり ナース版トリセツ:抗悪性腫瘍薬

    横上聖貴、竹島秀雄

    Brain Nursing   2014.6

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)   Publisher:MCメディカ出版  

  • A case of primary diffuse leptomeningeal gliomatosis.

    Yamasaki K, Yokogami K, Ohta H, Yamashita S, Uehara H, Sato Y , Takeshima H

    Brain Tumor Pathol.   2014.1

     More details

    Language:English   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   Publisher:Springer  

  • 脳膿瘍治療中にメトロニダゾール脳症をきたした1例

    齋藤清貴、米山匠、古賀治幸、田中隆、横上聖貴、児玉隆男、竹島秀雄

    脳神経外科速報   23 ( 1 )   82 - 88   2013.1

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   Publisher:メディカ出版  

  • 原発性脳腫瘍との鑑別に苦慮したtumefactive multiple sclerosisの一例

    新甫武也,内之倉俊朗,横上聖貴,上原久生,丸塚浩助,福島剛,塩見一剛,京楽格,小玉隆男,矢野貴徳,竹島秀雄

    脳神経外科ジャーナル   21 ( 8 )   625 - 630   2013.1

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)   Publisher:三輪書店  

display all >>

Presentations 【 display / non-display

  • 特発性脳脊髄減少症における腹側OSF leak部の同定

    横上聖貴

    第13回九州・山口ニューロスパイン研究会 

     More details

    Event date: 2019.11.9

    Language:Japanese   Presentation type:Oral presentation (general)  

  • SHH type TP53 mutad 髄芽腫におけるMYCNの機能解明

    横上聖貴

    日本脳神経外科学会第78回学術総会 

     More details

    Event date: 2019.10.9 - 2019.10.12

    Language:Japanese   Presentation type:Oral presentation (general)  

  • 片側椎弓切除術で治療した特発性脊髄硬膜外血腫の1例.

    横上聖貴、濵砂亮一

    第34回日本脊髄外科学会 

     More details

    Event date: 2019.6.20 - 2019.6.21

    Language:Japanese   Presentation type:Oral presentation (general)  

  • SHH type TP53 mutad medulloblastomaにおけるMYCNの機能解明

    横上聖貴

    第37回日本脳腫瘍病理学会 

     More details

    Event date: 2019.5.31 - 2019.6.1

    Language:Japanese   Presentation type:Oral presentation (general)  

  • グリオーマの遺伝子診断におけるHRM法の有用性とその限界.

    横上聖貴

    第36回日本脳腫瘍学会学術集会 

     More details

    Event date: 2018.12.2 - 2018.12.4

    Language:Japanese   Presentation type:Poster presentation  

display all >>

Grant-in-Aid for Scientific Research 【 display / non-display

  • EVI1によるPDGFRβ転写制御とグリオブラストーマ血管新生機構について

    Grant number:22K09237  2022.04 - 2027.03

    独立行政法人日本学術振興会  科学研究費補助金  基盤研究(C)

    水口 麻子、

      More details

    Authorship:Coinvestigator(s) 

  • 代謝経路再編成が概日リズム経路を介し、幹細胞性維持、細胞死回避に及ぼす影響の解明

    Grant number:22K09262  2022.04 - 2025.03

    独立行政法人日本学術振興会  科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

  • 神経幹細胞、神経膠芽腫癌幹細胞における転写因子Evi1 の機能解明

    2013.04 - 2016.03

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

    神経幹細胞、神経膠芽腫癌幹細胞における転写因子Evi1 の機能解明

  • 癌幹細胞分化誘導システムを利用した乏突起膠腫の新規分子マーカーの探索

    2008.04 - 2011.03

    科学研究費補助金  基盤研究(B)

      More details

    Authorship:Coinvestigator(s) 

    癌幹細胞分化誘導システムを利用した乏突起膠腫の新規分子マーカーの探索